You are cordially invited to attend this free, live interactive webinar.
RECELL® Spray-On Skin™ Cells:
An Innovation for Limb Salvage Wound Closure
Wounds not responding to conventional treatment methods often result in amputations. The risk increases for patients with comorbidities such as diabetes, hypertension, vascular deficits, and kidney disease. In this webinar, Lisa Gould, MD, PhD, FACS will discuss the use of RECELL Spray-On Skin Cells in limb salvage to achieve definitive closure of difficult-to-heal wounds while reducing donor site morbidity.
RECELL GO uses a small piece of the patient's skin to create a multi-phenotype suspension of Spray-On Skin Cells.1 The application of different cell types stimulates healing and repigmentation throughout the wound bed.2,3
RECELL GO provides Benefits Beyond Closure® versus standard of care:
Significantly less donor skin needed4
Fewer procedures for definitive closure4-6
Reduction in length of stay for burns <50% TBSA6-8
Improved aesthetic outcomes at the RECELL GO harvested donor site4
Reduced pain at the RECELL GO harvested donor site4
For more information on how to provide point-of-care, multi-cell regenerative wound healing with RECELL GO,4 visit:
avitamedical.com or call toll-free (833) 462-8482.
References:
Wood, FM, Giles N Stevenson A, Rea S, Fear M. Characterisation of the cell suspension harvested from the dermal epidermal junction using a Recell® kit. Burns. 2012; 38 (1):44-51.
Navarro FA, Stoner ML, Park CS, et al. Sprayed keratinocyte suspensions accelerate epidermal coverage in a porcine microwound model. J Burn Care Rehabil 2000;21:513–8.
Navarro FA, Stoner ML, Lee HB, et al. Melanocyte repopulation in full-thickness wounds using a cell spray apparatus. J Burn Care Rehabil. 2001;22:41–6.
Instructions for Use. RECELL GO™ Autologous Cell Harvesting Device.
Foster K, Bilir P, Kruger E, et al. Cost-effectiveness of RECELL® Autologous Cell Harvesting Device (ACHD) versus STSG for treatment of severe burns in the United States. Presented at the American Burn Association 2018 Annual Meeting, April 2018.
Kowal S, Kruger E, Bilir P, et al. Cost-Effectiveness of the Use of Autologous Cell Harvesting Device Compared to Standard of Care for Treatment of Severe Burns in the United States. Adv Ther. 2019;36(7):1715-1729.
Carter JE, Carson JS, Hickerson WL, et al. Length of Stay and Costs with Autologous Skin Cell Suspension Versus Split-Thickness Skin Grafts: Burn Care Data from US Centers. Adv Ther. 2022;39(11):5191-5202.
Carson JS, Carter JE, Hickerson WL, et al. Analysis of real-world length of stay data and costs associated with use of autologous skin cell suspension for the treatment of small burns in U.S. centers. Burns. 2023;49(3):607-614.
IMPORTANT SAFETY INFORMATION
INDICATIONS FOR USE: The RECELL GO Autologous Cell Harvesting Device is indicated for the treatment of thermal burn wounds and full-thickness skin defects. The RECELL GO Device is used by an appropriately licensed and trained healthcare professional at the patient’s point of care to prepare autologous Spray-On Skin Cells for direct application to acute partial-thickness thermal burn wounds in patients 18 years of age and older, or application in combination with meshed autografting for acute full-thickness thermal burn wounds in pediatric and adult patients and full-thickness skin defects after traumatic avulsion (e.g., degloving) or surgical excision (e.g., necrotizing soft tissue infection) or resection (e.g., skin cancer) in patients 15 years of age and older.
CONTRAINDICATIONS: RECELL GO is contraindicated for the treatment of: wounds clinically diagnosed as infected or with necrotic tissue present in the wound bed, patients with a known hypersensitivity to trypsin or compound sodium lactate (Hartmann’s) solution, and patients with a known hypersensitivity to anesthetics, adrenaline/epinephrine, povidone-iodine, or chlorhexidine solutions.
WARNINGS: Autologous use only. Control infections and excise all necrotic tissue on the wound bed prior to application of the meshed autograft and/or Spray-On Skin Cells. Wound beds treated with a cytotoxic agent (e.g., silver sulfadiazine) should be rinsed prior to application. Choose a donor site with no evidence of cellulitis or infection and process skin immediately. The enzyme is animal-derived and freedom from infectious agents cannot be guaranteed.
PRECAUTIONS: RECELL GO is not intended for use without a meshed autograft for the treatment of acute full-thickness burn wounds or full-thickness skin defects. The safety and effectiveness of the device have not been established for the treatment of: full-thickness skin defects on the hands and genitalia; full-thickness burn wounds in patients younger than 28 days of age; and partial-thickness burn wounds >320 cm2, on the hands and articulating joints, or in patients with wounds totaling >20% TBSA.
INSTRUCTIONS FOR USE: Consult the Instructions for Use at avitamedical.com for complete Safety Information prior to using RECELL GO.